Essity AB ESSITY B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Keep the core position but reassess the case: monitor Cevian’s agenda/communications and management’s response, plus evidence that price/mix stabilises. Consider adding only if strategic steps become concrete or price/mix turns; reduce if margin pressure worsens without credible countermeasures.
Cevian as an active owner and the ongoing tissue process represent major structural catalysts while new sell recommendations and cost concerns warrant continued review.
Sentiment has turned more cautious after downgrades and concerns over margin pressure from higher input costs, despite support from buybacks and strategic reviews.
NEUTRAL is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 23 Oct 2026 — Report published 22 October showed margin beating consensus despite cost pressure, driven by higher revenue and ongoing buyback program.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (7) — follow the company freeAbout the company
Essity AB is a global producer of hygiene and health products with strong brands such as TENA and Tork. The company is mature and cash-flow generative, focusing on margin improvement through efficiency programs, buybacks, and selective acquisitions.
Bull case
Cevian as an active owner can drive portfolio changes and efficiencies that improve margins and capital allocation.
Bear case
Weak organic growth, price pressure and sell recommendations increase the risk of lower margins if input costs continue to rise.
Why this signal
Cevian as an active owner and the ongoing tissue process represent major structural catalysts while new sell recommendations and cost concerns warrant continued review.
Recent news
Essity published the Q3 report on 22 October with net sales of SEK 36.06 bn and adjusted EBITA margin of 13.1 % beating consensus despite cost pressure. An agreement was signed to acquire Kenvue’s feminine care business in Brazil with completion in Q2 2027. Weekly buybacks continue under the SEK 3 bn programme.